Plus Therapeutics, Inc.
PSTV
$0.26
-$0.01-2.19%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -2.15% | 0.50% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -2.15% | 0.50% | |||
| Cost of Revenue | 20.73% | 95.51% | |||
| Gross Profit | -51.49% | -821.53% | |||
| SG&A Expenses | 21.06% | 104.70% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 20.92% | 100.79% | |||
| Operating Income | -28.11% | -191.42% | |||
| Income Before Tax | -29.17% | -185.87% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -29.17% | -185.87% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -29.17% | -185.87% | |||
| EBIT | -28.11% | -191.42% | |||
| EBITDA | -27.06% | -201.51% | |||
| EPS Basic | -0.73% | -267.48% | |||
| Normalized Basic EPS | -0.78% | -138.65% | |||
| EPS Diluted | -1.94% | -533.85% | |||
| Normalized Diluted EPS | -0.78% | -266.88% | |||
| Average Basic Shares Outstanding | 28.16% | 122.01% | |||
| Average Diluted Shares Outstanding | 28.16% | -48.64% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||